Challenges in the Development of Drug/Device and Biologic/Device Combination Products in the United States and European Union

Abstract

Compared with single-entity treatments, multientity or combination products have the potential to provide enhanced therapeutic utility. Because they involve components that would normally be overseen by different branches of health authorities (eg, different FDA centers), they raise numerous scientific, regulatory, policy, and review management challenges. This article summarizes the current status of the evolving combination product development landscape and potential options to address key challenges facing combination product developers. Continued collaboration and transparency among regulators, combination product developers, and other stakeholders is essential to streamlining the global combination product development and review process to ensure the availability of high-quality new products that are being used in a way that is safe and effective.

Keywords

Drug Information Association device Office of Combination Products

Get full access to this article

View all access options for this article.

References

Allison

Industry perspective on combination products development. Paper presented at: Drug Information Association Meeting on Combination Products; November 2013; Alexandria, VA.

FDA. Combination product definition. http://www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm118332.htm. Accessed January 5, 2014.

Vollebregt

Combination products: bridging US-EU. Paper presented at: Drug Information Association Meeting on Combination Products; November 2013; Alexandria, VA.

European Commission. EU proposals on medical devices: citizens summary. http://ec.europa.eu/health/medical-devices/files/revision_docs/citizen_summary_20120926_en.pdf. Accessed April 10, 2014.

European Commission. Citizens summary on the EU proposals on medical devices. http://ec.europa.eu/health/medical-devices/files/revision_docs/citizen_summary_20120926_en.pdf. Accessed April 14, 2014.

EUDAMED. European database for medical devices webpage. http://ec.europa.eu/idabc/en/document/5362/5637.html. Accessed April 29, 2014.

Combination products: the future of medicine. http://www.healthcarepackaging.com/applications/healthcare/combination-products-future-medicine. Accessed February 27, 2014.

Safe Medical Device Act of 1990, Pub L No. 101–629, November 28, 1990.

Food, Drug, and Cosmetic Act §503(g)(1), 21 USC §353(g)(1) (1990).

10.

FDA. Guidance on how to write a request for designation (RFD) http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM251544.pdf. Accessed April 20, 2014.

11.

Lauritsen

Nguyen

. Combination products regulation at the FDA. Clin Pharmacol Ther. 2009;85 (5):468–470.

12.

FDA. Manual of standard operating procedures and policies intercenter consultative/collaborative review process: version 4. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126016.pdf. Accessed April 15, 2014.

13.

FDA Office of Combination Products. FY 2006 performance report to Congress. http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/PerformanceReports/CombinationProducts/UCM136071.pdf. Accessed April 10, 2014.

14.

15.

16.

Nguyen

. Combination product update. Paper presented at: Drug Information Association Meeting on Combination Products; November 2013; Alexandria, VA.

17.

Weigh in on your combination product packaging challenges. http://www.healthcarepackaging.com/applications/healthcare/weigh-your-combination-product-packaging-challenges. Accessed March 7, 2014.

18.

European Medicines Agency Innovation Task Force. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000334.jsp&mid=WC0b01ac05800ba1d9. Accessed April 10, 2014.

19.

Baker

Multi-market access challenges: Europe. Paper presented at: Drug Information Association Meeting on Combination Products; November 2013; Alexandria, VA.

20.

FDA. Early development considerations for innovative combination products. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126054.pdf. Accessed February 28, 2014.

21.

21 CFR part 4. Current good manufacturing practice requirements for combination products. January 22, 2013.

22.

Final rule on combination products cGMPs. Fed Regist. 2013;78(14).

23.

FDA. Draft guidance on current good manufacturing practice for combination products. http://www.fda.gov/regulatoryinformation/guidances/ucm126198.htm. Accessed April 2, 2014.

24.

Weiner

Current good manufacturing practices for combination products final rule. Paper presented at: Drug Information Association Meeting on Combination Products; November 2013; Alexandria, VA.

25.

Wesolowski

Combination product GMP requirements. Paper presented at: Drug Information Association Meeting on Combination Products; November 2013; Alexandria, VA.

26.

FDA. Guidance for industry: technical considerations for pen, jet, and related injectors intended for use with drugs and biological products. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM147095.pdf. Accessed September 19, 2014.

27.

FDA. Special considerations for medical devices. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/ucm134578.htm#kits. Accessed April 15, 2014.